Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis.

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) pipeline Target constitutes close to 7 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 2 and 2 respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Gastrointestinal, Hematological Disorders, Immunology, Toxicology and Women's Health which include indications Coronavirus Disease 2019 (COVID-19), Non-Small Cell Lung Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alopecia Areata, Anal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Cervical Intraepithelial Neoplasia (CIN), Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Esophageal Cancer, Follicular Lymphoma, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Tumor, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus Infections, Hypopharyngeal Cancer, Idiopathic CD4 Lymphocytopenia, Kaposi Sarcoma, Laryngeal Cancer, Lymphocytopenia, Malignant Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Mycobacterium avium Infections, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Primary Sjogren's Syndrome, Progressive Multifocal Leukoencephalopathy, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sepsis, Sezary Syndrome, Small-Cell Lung Cancer, Squamous Cell Carcinoma, Triple-Negative Breast Cancer (TNBC) and Ulcerative Colitis.

The latest report Interleukin 7 Receptor Subunit Alpha - Drugs In Development, 2022, outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)
  • The report reviews Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) – Overview
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) – Companies Involved in Therapeutics Development
Allterum Therapeutics LLC
Genexine Inc
Medikine Inc
OSE Immunotherapeutics SA
RevImmune SAS
Zura Bio Ltd
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) – Drug Profiles
CYT-107 – Drug Profile
efineptakin alfa – Drug Profile
lusvertikimab – Drug Profile
MDK-701 – Drug Profile
Monoclonal Antibody to Antagonize IL7R for Acute Lymphocytic Leukemia – Drug Profile
OSE-703 – Drug Profile
ZB-168 – Drug Profile
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) – Dormant Products
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) – Discontinued Products
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) – Product Development Milestones
Featured News & Press Releases
Dec 12, 2022: OSE Immunotherapeutics announces latest preclinical efficacy data on its Anti-IL-7 receptor antagonist OSE-127 in acute lymphoblastic leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting
Nov 11, 2022: New evidence of NeoImmuneTech's NT-I7 clinical efficacy in combination with pembrolizumab in relapsed/refractory (r/r) gastrointestinal tumors
Nov 10, 2022: Medikine presents preliminary results of a single-dose phase 1 healthy subject study of MDK-703, a peptide-based mimetic of interleukin-7 (IL-7)
Nov 04, 2022: NeoImmuneTech to present first data on NT-I7 (efineptakin alfa) in combination with CAR-T tisagenlecleucel, at 2022 ASH Annual Meeting
Nov 03, 2022: Servier and OSE Immunotherapeutics announce completion of patient enrollment in the Phase 2a clinical trial of OSE-127/S95011 in primary Sjogren’s Syndrome
Nov 03, 2022: OSE Immunotherapeutics announces award for OSE-127's upcoming oral presentation in acute lymphoblastic leukemia
Oct 05, 2022: NeoImmuneTech to present new advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting
Oct 05, 2022: Medikine to present preliminary phase 1 clinical trial results for MDK-703 at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)
Sep 13, 2022: NeoImmuneTech's NT-I7 creates a more immunogenic tumor microenvironment when associated with pembrolizumab
Jul 20, 2022: Medikine begins dosing Phase I trial of solid tumor candidate
Jul 13, 2022: FDA grants orphan drug designation (ODD) status to Neoimmunetech's NT-I7 for the treatment of glioblastoma multiforme
Jun 14, 2022: A Study in Nature Communications reports that NeoImmuneTech's NT-I7 enhances CAR-T Cell expansion, persistence and anti-tumor activity
Jun 13, 2022: NeoImmuneTech to present at upcoming BIO International Convention
Jun 07, 2022: Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer
Jun 06, 2022: NeoImmuneTech's lead asset NT-I7 (efineptakin alfa) shows preliminary anticancer activity in combination with check-point inhibitors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development by Stage of Development, 2022
Table 2: Number of Products under Development by Therapy Areas, 2022
Table 3: Number of Products under Development by Indications, 2022
Table 4: Number of Products under Development by Indications, 2022 (Contd..1)
Table 5: Number of Products under Development by Indications, 2022 (Contd..2)
Table 6: Number of Products under Development by Companies, 2022
Table 7: Products under Development by Companies, 2022
Table 8: Products under Development by Companies, 2022 (Contd..1)
Table 9: Products under Development by Companies, 2022 (Contd..2)
Table 10: Products under Development by Companies, 2022 (Contd..3)
Table 11: Number of Products by Stage and Mechanism of Actions, 2022
Table 12: Number of Products by Stage and Route of Administration, 2022
Table 13: Number of Products by Stage and Molecule Type, 2022
Table 14: Pipeline by Allterum Therapeutics LLC, 2022
Table 15: Pipeline by Genexine Inc, 2022
Table 16: Pipeline by Medikine Inc, 2022
Table 17: Pipeline by OSE Immunotherapeutics SA, 2022
Table 18: Pipeline by RevImmune SAS, 2022
Table 19: Pipeline by Zura Bio Ltd, 2022
Table 20: Dormant Products, 2022
Table 21: Dormant Products, 2022 (Contd..1)
Table 22: Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development by Stage of Development, 2022
Figure 2: Number of Products under Development by Therapy Areas, 2022
Figure 3: Number of Products under Development by Top 10 Indications, 2022
Figure 4: Number of Products by Mechanism of Actions, 2022
Figure 5: Number of Products by Stage and Mechanism of Actions, 2022
Figure 6: Number of Products by Routes of Administration, 2022
Figure 7: Number of Products by Stage and Routes of Administration, 2022
Figure 8: Number of Products by Molecule Types, 2022
Figure 9: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings